Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy

Journal of Digestive Diseases

Volumn 11, Issue 5, 2010, Pages 266-276

  Schirbel, Anja ^a   Fiocchi, Claudio ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Crohn's disease; Genetics; Inflammatory bowel disease; Intestinal microbiota; Pathogenesis; Ulcerative colitis

Indexed keywords

ABATACEPT; ABT 874; ADALIMUMAB; ALICAFORSEN; BASILIXIMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CERTOLIZUMAB PEGOL; DACLIZUMAB; FONTOLIZUMAB; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; NATALIZUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; ROSIGLITAZONE; SOTRASTAURIN; TACROLIMUS; TETOMILAST; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; USTEKINUMAB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VEDOLIZUMAB; VISILIZUMAB;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CROHN DISEASE; DENDRITIC CELL; DNA POLYMORPHISM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOBAL CHANGE; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; MACROPHAGE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINES;

EID: 77957238924     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00449.x     Document Type: Review

References (114)

1. Fiocchi C. Inflammatory bowel disease pathogenesis: therapeutic implications. Chin J Dig Dis 2005, 6:6-9.
2. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis 2007, 8:171-8.
3. Arend P, Martini GA. Ulcerative colitis. Etiologic unity or polyetiologic syndrome? Am J Proctol 1970, 21:331-6.
4. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004, 11:195-204.
5. Korzenik JR. Past and current theories of etiology of IBD. Toothpaste, worms, and refrigerators. J Clin Gastroenterol 2005, 39:S59-S65.
6. Xavier RJ, Podolsky D. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-34.
7. Fiocchi C. Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig Dis 2009, 226-35.
8. Kaser A, Zeissing S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
9. Cadwell K, Patel KK, Maloney NS. Virus-plus-susceptibility gene interaction determines Crohn's disease Atg16L1 phenotypes in intestine. Cell 2010, 141:1135-45.
10. Baumgart D, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-57.
11. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-17.
12. Ouyang Q, Tandon R, Goh K-L, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 2005, 21:408-13.
13. Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008, 103:3167-82.
14. Goh KL, Xiao S-D. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis 2009, 10:1-6.
15. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis 2010, 11:76-82.
16. Hilmi I, Singh R, Ganesananthan S. Demography and clinical course of ulcerative colitis in a multiracial Asian population: a nationwide study from Malaysia. J Dig Dis 2009, 10:15-20.
17. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010, 11:134-47.
18. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004, 10:848-59.
19. Strachan D. Hay fever, hygiene, and household size. Br Med J 1989, 299:1259-60.
20. Yazdanbakhsh M, Kremsner PG, vanRee R. Allergy, parasites, and the hygiene hypothesis. Science 2002, 296:490-4.
21. Feillet H, Bach J-F. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr Opin Gastroenterol 2004, 20:560-4.
22. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008, 57:1185-91.
23. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 2008, 14:165-73.
24. Lakatos PL. Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 2009, 27:215-25.
25. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324:84-8.
26. Hugot J-P, Chamaiilard M, Zouali H. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
27. Ogura Y, Bonen DK, Inohara N. A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-6.
28. Duerr RH, Taylor KD, Brant SR. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-3.
29. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447:661-73. Wellcome Trust Case Control Consortium
30. Barrett JC, Hansoul S, Nicolae DL. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-62.
31. McGovern DPB, Gardet A, Torkvist L. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010, 42:332-7.
32. Imielinski M, Baldassano RN, Griffiths A. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009, 41:1335-40.
33. Yamazaki K, McGovern D, Ragoussis J. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2007, 14:3499-506.
34. Thiebaut R, Kotti S, Jung C. TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol 2009, 104:384-91.
35. Michelsen KS, Thomas LS, Taylor KD. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. Plos One 2009, 4. e4719. Epub 2009 Mar 5
36. Massey D, Parkes M. Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. Gut 2007, 56:1489-92.
37. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008, 8:458-66.
38. Deretic V. Links between autophagy, innate immunity, inflammation and Crohn's disease. Dig Dis 2009, 27:246-51.
39. Cadwell K, Stappenbeck TS, Virgin HW. Role of autophagy and autophagy genes in inflammatory bowel disease. Curr Top Microbiol Immunol 2009, 335:141-67.
40. Franchimont D, Vermeire S, ElHousni H. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-92.
41. Kaser A, Lee A-H, Franke A. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-56.
42. von Stein P, Lofberg R, Kuznetsov NV. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology 2008, 134:1869-81.
43. Weersma RK, Stokkers PC, van Bodegraven AA. Molecular prediction of disease risk in a large Dutch Crohn's disease cohort. Gut 2009, 58:388-95.
44. Arijs I, Li K, Toedter G. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58:1612-19.
45. Chiodini RJ, Kruiningen HJV, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984, 29:1073-9.
46. Selby W, Pavli P, Crotty B. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007, 132:2313-19.
47. Darfeuille-Michaud A, Neut C, Barnich N. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998, 115:1405-13.
48. Darfeuille-Michaud A, Boudeau J, Bulois P. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-21.
49. Rolhion N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:1277-83.
50. Elson CO, McCracken VJ, Dimmit RA, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005, 206:260-76.
51. Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 2004, 20:318-27.
52. Mow WS, Vasiliauskas EA, Lin Y-C. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-24.
53. Dubinsky MC, Kugathasan S, Mei L. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008, 6:1105-11.
54. Duerkop BA, Vaishnava S, Hooper LV. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009, 31:368-76.
55. Ivanov II, Littman DR. Segmented filamentous bacteria take the stage. Mucosal Immunol 2010, 3:209-12.
56. Sartor RB. Microbial influences in inflammatory bowel disease. Gastroenterology 2008, 134:577-94.
57. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-23.
58. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet 2003, 361:512-19.
59. Guarner F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol 2005, 21:414-18.
60. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009, 326:1694-7.
61. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-5.
62. Sokol H, Pigneur B, Watterlot L. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008, 105:16731-6.
63. Schultz C, VandenBerg FM, Kate FWT, Tytgat GN, Dankert J. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999, 117:1089-97.
64. Swidsinski A, Ladhoff A, Pernthaler A. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54.
65. Seksik P, Rigottier-Gois L, Gramet G. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003, 52:237-42.
66. Ott SJ, Musfeldt M, Wenderoth DF. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53:685-93.
67. Manichanh C, Rigottier-Gois L, Bonnaud E. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic analysis. Gut 2006, 55:205-11.
68. Sokol H, Seksik P, Rigottier-Gois L. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:106-11.
69. Menendez A, Ferreira RBR, Finlay BB. Defensins keep the peace too. Nat Immunol 2010, 11:49-50.
70. Wehkamp J, Salzman NH, Porter E. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005, 102:18129-34.
71. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007, 56:1240-7.
72. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophage: unique effector cells of the innate immune system. Immunol Rev 2005, 206:149-59.
73. Selby WS, Poulter LW, Hobbs S, Jewell DP, Janossy G. Heterogeneity of HLA-DR positive histiocytes of human intestinal lamina propria: a combined histochemical and immunological analysis. J Clin Pathol 1983, 36:379-84.
74. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994, 35:669-74.
75. Rugtveit J, Nilsen EM, Bakka A, Carlsen H, Brandtzaeg P, Scott H. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997, 112:1493-505.
76. Kamada N, Hisamatsu T, Okamoto S. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn's disease via IL-23/IFN-gamma axis. J Clin Invest 2008, 118:2269-80.
77. Korzenik JR, Dieckegraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 2000, 45:1121-9.
78. Smith AM, Rahman FZ, Hayee B. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009, 206:1883-97.
79. Casanova J-L, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med 2009, 206:1839-43.
80. Rescigno M, diSabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest 2009, 119:2441-50.
81. Bilsborough J, Viney JL. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology 2004, 127:300-9.
82. Hart AL, Al-Hassi HO, Rigby RJ. Characteristics of intestinal dendritic cells in inflammatory bowel disease. Gastroenterology 2005, 129:50-65.
83. MacDermott RP, Nash GS, Bertovich MJ. Alterations of IgM, IgG, and IgA synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology 1981, 81:844-52.
84. MacDermott RP, Nash GS, Bertovich MJ, Seiden MV, Bragdon MJ, Beale MG. Altered patterns of secretion of monomeric IgA and IgA subclass 1 by intestinal mononuclear cells in inflammatory bowel disease. Gastroenterology 1986, 91:379-85.
85. Scott MG, Nahm MH, Macke K, Nash GS, Bertovich MJ, MacDermott RP. Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease, and controls. Clin Exp Immunol 1986, 66:209-15.
86. Perosa F, Prete M, Racanelli V. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010, 267:269-77.
87. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-57.
88. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991, 12:256-7.
89. Annunziato F, Romagnani S. Do studies in human better depict Th17 cells? Blood 2009, 114:2213-19.
90. Annunziato F, Cosmi L, Santarlasci V. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-61.
91. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009, 11:257.
92. Cosmi L, Maggi L, Santarlasci V. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 2010, 125:222-30.
93. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010, 327:1098-102.
94. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114:1198-208.
95. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, and subphenotypes. Nat Immunol 2009, 10:689-95.
96. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-88.
97. Weaver CT, Hatton RD. Interplay between the TH17 and Treg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009, 9:883-9.
98. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: success and failures in human disease. Gut 2002, 50(III):iii60-iii4. Suppl
99. Parronchi P, Romagnani P, Annunziato F. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997, 150:823-32.
100. Monteleone G, Biancone L, Marasco R. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-78.
101. Fujino S, Andoh A, Bamba S. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
102. Monteleone G, Monteleone I, Fina D. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005, 128:687-94.
103. Fuss IJ, Heller F, Boirivant M. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004, 113:1490-7.
104. Heller F, Florian P, Bojarski C. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterlogy 2005, 129:550-64.
105. Fantini MC, Monteleone G, MacDonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflam Bowel Dis 2007, 13:1419-23.
106. Makita S, Kanai T, Oshima S. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004, 173:3119-30.
107. Maul J, Loddenkemper C, Mundt P. Peripheral and intestinal regulatory CD4+CD25+high T cells in inflammatory bowel disease. Gastroenterology 2005, 128:1868-78.
108. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J Immunol 2005, 174:5814-22.
109. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006, 5:197-209.
110. Neurath MF, Finotto S. Translating inflammatory bowel disease research into clinical medicine. Immunity 2009, 31:357-61.
111. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-97.
112. Editorial. Embrace the complexity. Nat Immunol 2009, 10:325.
113. Fraser IDC, Germain RN. Navigating the network: signaling cross-talk in hematopoietic cells. Nat Immunol 2009, 10:327-31.
114. van der Greef J, McBurney RN. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov 2005, 4:961-7.